Menu
  • Join
  • Login
  • Contact
 

Search abstracts


SAFETY ANALYSIS OF PATIENTS TREATING WITH EGFR-TKIS AT A MEDICAL CENTER IN MIDDLE TAIWAN

  • At: 2015 FIP Congress in Düsseldorf (Germany)
  • Type: Poster
  • By: ZHENG, Hong-Wen (Chung Shan Medical Universaty Hospital, Pharmacy, Taichung City, China Taiwan)
  • Co-author(s): Hong-Wen Zheng
  • Abstract:

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been approved in the first-line therapy of EGFR mutation patients with non-small cell lung cancer by FDA. In our hospital, patients with EGFR mutation-positive lung cancer can be offered a therapeutic alternative of gefitinib, erlotinib and afatinib. 

    AEs reported due to

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses